To the Editor:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic affecting over 4.5 million people as of May 15, 2020 (1). Acute respiratory distress syndrome (ARDS) has been reported in 5% of SARS-CoV-2 infected cases (2) and is associated with increased duration of mechanical ventilation and mortality (3, 4). There is no proven therapy for SARS-CoV-2-related ARDS, and the use of corticosteroids is controversial (5). The World Health Organization recommend against the routine use of steroids in patients SARS-CoV-2 pneumonia (6), yet the Society of Critical Care Medicine recently issued a weak recommendation supporting the use of corticosteroids in patients with SARS-CoV-2-related ARDS (7). There is no study to date, which has so far addressed the effect of corticosteroids administration on clinical outcome in mechanically ventilated patients with SARS-CoV-2-related ARDS.

This is a retrospective analysis of adult, mechanically ventilated patients, who were admitted to the ICU between March 20, 2020, and April 17, 2020, for SARS-CoV-2-related ARDS. This study was approved by the Institutional Review Board (IRB) at Albany Medical Center (IRB number 5826). SARS-CoV-2 infection was diagnosed via real-time reverse transcription-polymerase chain reaction from a nasopharyngeal swab in these patients. ARDS was defined by the Berlin criteria. The cohort was divided into two groups based on corticosteroid administration. The decision to administer corticosteroids was made by the treating clinician; some clinicians were routinely using steroid early in the course after excluding coinfection with other virus or bacterial infection and others were not.

The primary outcome variable was ventilator-free days at day 28. This is a composite outcome that aggregates length of mechanical ventilation and survival. Patients who remain on mechanical ventilation longer than 28 days or who die while on mechanical ventilation are given zero free days. Secondary outcome variable was ICU-free days at day 30 and hospital length of stay at day 30. To validate the association between the main covariable (steroids administration) associated with the outcome measures, we determined baseline similarity in terms of chronic disease (Charlson comorbidity index) and acute disease burden (Acute Physiology and Chronic Health Evaluation II, Sequential Organ Failure Assessment, and Simplified Acute Physiology Score II) between the groups. Minitab statistical software was used for analysis. Continuous variables were expressed as mean, median, and interquartile range (interquartile range [IQR], 25–75th percentile). For normally distributed data-independent sample t tests were used to assess statistical significance (two-tailed alpha of 0.05). For data not demonstrating normality, including the primary outcome variable, statistical significance was assessed using Mann-Whitney U nonparametric test. Categorical variables are expressed as numbers and percentages and statistical significance assessed using Pearson chi-square test or Fisher exact test when expected values are less than five.

We analyzed 61 mechanically ventilated patients with SARS-CoV-2-related ARDS. Study cohort had mean age of 60.2 years and were predominantly male (66%); Caucasians (28%) and...
## TABLE 1. Comparison of Baseline Characteristics and Outcomes Between Corticosteroid Versus Noncorticosteroid Groups

| Variables                               | Corticosteroid, n = 38 | Noncorticosteroid, n = 23 | p* |
|-----------------------------------------|------------------------|---------------------------|----|
| **Sex, n (%)**                          |                        |                           |    |
| Male                                    | 28 (74)                | 12 (52)                   | 0.10|
| Female                                  | 10 (26)                | 11 (48)                   |    |
| **Age, yr**                             |                        |                           |    |
| Mean, median (IQR)                      | 57.9, 57 (48–68)       | 64.1, 64 (56–73)          | 0.10|
| **Ethnicities, n (%)**                  |                        |                           |    |
| White                                   | 9 (24)                 | 8 (35)                    | 0.61|
| Black                                   | 9 (24)                 | 3 (13)                    |    |
| Hispanic                                | 11 (29)                | 6 (26)                    |    |
| Asian                                   | 1 (2)                  | 2 (9)                     |    |
| Other                                   | 8 (21)                 | 4 (17)                    |    |
| **Charlson score, mean, median (IQR)**  | 2.8, 2 (1–3)           | 3.2, 3 (2–4)              | 0.51|
| **Severity indexes, mean, median (IQR)**|                        |                           |    |
| Acute Physiologic Assessment and Chronic Health Evaluation II | 23.2, 22.5 (18–27) | 24.0, 22 (18–31) | 0.65|
| Simplified Acute Physiology Score II    | 56.1, 53 (47–61)       | 61.2, 58 (53–70)          | 0.12|
| Sequential Organ Failure Assessment     | 8.8, 8 (7–10)          | 9.5, 9 (7–12)             | 0.40|
| **Inflammatory markers, mean, median (IQR)** |                     |                           |    |
| Ferritin (ng/mL)                        | 1,081, 1,043 (429–1,582)| 808, 680 (378–1,102)      | 0.18|
| C-reactive protein (mg/L)               | 199, 201.8 (91–266)    | 162.1, 156 (45–256)       | 0.21|
| D-dimer (mg/L fibrinogen equivalent units) | 12.6, 4.7 (1.7–17.5) | 34.0, 19.4 (20.0–57.7) | 0.03|
| Procalcitonin (ng/mL)                   | 8.60, 1.4 (0.6–4.9)    | 2.2, 0.7 (0.3–2.4)        | 0.13|
| Lactate (mmol/L)                        | 1.3, 1.2 (0.9–1.6)     | 1.5, 1.3 (1.0–1.7)        | 0.23|
| Fibrinogen                              | 608.9, 645 (437–759)   | 484.3, 479 (373–656)      | 0.02|
| **Respiratory variables, mean, median (IQR)** |                 |                           |    |
| PaO₂/FiO₂ ratio                         | 161.8, 151 (983–195)   | 155.1, 135 (93–210)       | 0.75|
| Static compliance                       | 36.1, 35.2 (27–42)     | 45.7, 40 (27.1–50.3)      | 0.25|
| Plateau pressure                        | 21.8, 21 (17–25)       | 20.2, 21 (18–23)          | 0.30|
| **Treatment, n (%)**                    |                        |                           |    |
| Hydroxychloroquine                      | 33 (87)                | 20 (87)                   | 0.99|
| Antibiotics                             | 38 (100)               | 23 (100)                  | > 0.99|
| Antiviral                               | 1 (3)                  | 0 (0)                     | > 0.99|
| Interleukin-6 antagonist                 | 2 (5)                  | 0 (0)                     | > 0.99|
| Convalescent plasma                     | 17 (45)                | 5 (22)                    | 0.07|
| **Primary outcome, mean, median (IQR)** |                        |                           |    |
| 28-d ventilator-free day                | 10.2, 7 (0–22.25)      | 4.7, 0 (0–11)             | 0.01|
| 30-d ICU-free day                       | 9.5, 1.5 (0–23)        | 6.7, 0 (0–18)             | 0.17|
| 30-d hospital-free day                  | 5.6, 0 (0–12)          | 1.6, 0 (0–0)              | 0.07|

IQR = interquartile range.

*Student t test for normally distributed data; Mann-Whitney U test for non-normally distributed data; and Pearson χ² test for categorical data or Fisher exact test if expected values < 5.

Boldface values indicate significant p value.
ARDs. In this study, Wu et al (8) reported improved survival with corticosteroids on outcome in patients with SARS-CoV-2-related ARDS. There is only one study to date, reporting the effect of corticosteroids from a diverse COVID population with different diseases burdens. There is one study to date, reporting the effect of corticosteroids on outcome in patients with SARS-CoV-2-related ARDS. In this study, Wu et al (8) reported improved survival in patients with SARS-CoV-2-related ARDS who received methylprednisolone as compared with who did not (23/50 [46%] vs 21/34 [62%]; p = 0.03). Patient who received methylprednisolone were sicker, despite of this baseline difference, there was significant mortality benefit.

In a retrospective analysis from Wuhan focused on critically ill patients with SARS-CoV-2, Yang et al (2) reported higher use of corticosteroids among survivors (14/20; 70%) as compared with nonsurvivors (16/32; 50%). Another retrospective study from Wuhan, among hospitalized patients with SARS-CoV-2 infection, there was less common use of corticosteroids among survivors (31/137; 31%) as compared with nonsurvivors (26/52; 48%) (9). However, these studies were not designed to analyze the effect of corticosteroids on specific clinical outcomes.

Our analysis has several limitations. First, this is a retrospective observational study that inferentially evaluate corticosteroids-related outcomes. Although the decision to administer corticosteroid was based on clinician preference, there was no predefined criteria to make patients eligible for that treatment. However, there was no significant difference observed in baseline characteristics and severity score in both groups, which indicates that the selection is unlikely to be biased by clinical factors. Second, this is a single center experience with relatively small sample size, which was not powered to determine mortality as a main outcome. Third, this analysis was only limited to the mechanically ventilated SARS-CoV-2-related ARDS patients, and therefore our findings cannot be generalized to all SARS-CoV-2 patients.

In summary, our analysis showed that the corticosteroids administration was associated with significant improvement in ventilator-free days at day 28, but no significant improvement in hospital- and ICU-free days at day 30 in mechanically ventilated SARS-CoV-2-related ARDS.

Dr. Feustel received funding as a statistical consultant for Transonic Systems, Scientific advisor with shares in Penrose TherapeuTx, LLC. Dr. Jaitovich received funding from National Institutes of Health under the award number K01-HL130704 and by the Collins Family Foundation Endowment. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Dr. Chopra is the guarantor of the article and takes responsibility for the integrity of the work, from inception to published article. Dr. Feustel was involved in performed statistical analysis. Drs. Chieng, Austin, and Jain helped with the data collection. All authors contributed to the writing of the article.

ACKNOWLEDGMENTS
The authors would like to thank Jeanette Mullins, BS, for her work on the data collection tool.
Amit Chopra, MD, Hau C. Chieng, MD, Adam Austin, MD, Anupama Tiwari, MD, Swati Mehta, MD, Amit Nautiyal, MD, Ali Hani Al-Tarbsheh, MD, Esha Jain, BA, Paul J. Feustel, PhD, Boris Shkolnik, MD, Ariel Jaitovich, MD

REFERENCES
1. Johns Hopkins University: From Johns Hopkins Coronavirus Resource Center. 2020. Available at: https://www.coronavirus.jhu.edu. Accessed April 12, 2020
2. Yang X, Yu Y, Xu J, et al: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020; 8:475–481
3. Grasselli G, Zangrillo A, Zanella A, et al: Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323:1574–1581
4. Richardson S, Hirsch JS, Narasimhan M, et al: Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052–2059
5. Russell CD, Millar JE, Baillie JK: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395:473–475
6. World Health Organization: Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected. 2020. Available at: https://apps.who.int/iris/handle/10665/331446. Accessed April 12, 2020
7. Poston JT, Patel BK, Davis AM: Management of critically ill adults with COVID-19. JAMA 2020; 323:1839–1841
8. Wu C, Chen X, Cei Y, et al: Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 58:713–714
9. Zhou F, Yu T, Du R, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395:1054–1062
DOI: 10.1097/CCE.000000000000143